Seipin, a protein encoded by the Berardinelli-Seip congenital lipodystrophy type 2 (BSCL2) gene, is famous for its key role in the biogenesis of lipid droplets and type 2 congenital generalised lipodystrophy (CGL2). BSCL2 gene mutations result in genetic diseases including CGL2, progressive encephalopathy with or without lipodystrophy (also called Celia’s encephalopathy), and BSCL2-associated motor neuron diseases. Abnormal expression of seipin has also been found in hepatic steatosis, neurodegenerative diseases, glioblastoma stroke, cardiac hypertrophy, and other diseases. In the current study, we comprehensively summarise phenotypes, underlying mechanisms, and treatment of human diseases caused by BSCL2 gene mutations, paralleled by animal studies including systemic or specific Bscl2 gene knockout, or Bscl2 gene overexpression. In various animal models representing diseases that are not related to Bscl2 mutations, differential expression patterns and functional roles of seipin are also described. Furthermore, we highlight the potential therapeutic approaches by targeting seipin or its upstream and downstream signalling pathways. Taken together, restoring adipose tissue function and targeting seipin-related pathways are effective strategies for CGL2 treatment. Meanwhile, seipin-related pathways are also considered to have potential therapeutic value in diseases that are not caused by BSCL2 gene mutations.
Hypertriglyceridaemia (HTG) is an increasingly recognised aetiology of acute pancreatitis (AP), driven by the global rise in metabolic disorders. Although traditionally defined by triglyceride levels ≥ 1000 mg/dL, emerging evidence suggests a continuum of risk in which both genetic predisposition and secondary metabolic stressors contribute to disease onset and severity. Mechanistically, HTG-AP is characterised by lipotoxic injury mediated by free fatty acids, microcirculatory dysfunction, and amplified inflammatory responses, resulting in increased risk of organ failure and recurrence compared with AP of other aetiologies. Recent guideline updates emphasise early risk stratification, goal-directed supportive care, and prompt identification of underlying causes; however, HTG-specific management strategies remain heterogeneous. While insulin therapy and extracorporeal lipid removal techniques (e.g., plasmapheresis) are widely used, high-quality evidence supporting their superiority is limited. Long-term prevention relies on aggressive lipid control and modification of metabolic risk factors. This review provides a comprehensive synthesis of the aetiology, pathophysiology, clinical characteristics, and management of HTG-AP, highlighting recent advances, ongoing controversies, and future directions towards precision medicine.
Acute inflammatory disorders, including acute lung injury, acute pancreatitis, ischaemia–reperfusion injury, and sepsis, are major clinical challenges characterised by rapid progression, a characteristic cytokine storm, and high mortality rates. The receptor for advanced glycation end-products (RAGE) serves as a pivotal multi-ligand pattern recognition receptor that integrates PAMPs and DAMPs. Excessive RAGE engagement triggers detrimental signalling cascades, notably NF-κB and MAPKs, which exacerbate hyperinflammation and lead to progressive organ dysfunction. Consequently, the RAGE axis represents a potent therapeutic target for mitigating hyperinflammation and improving clinical outcomes in acute inflammatory disorders. While initial pharmacological efforts focused on synthetic inhibitors and biologics, there is a shifting focus toward bioactive alternatives with high safety profiles. Here, we present recent molecular insights into RAGE-mediated pathogenesis in acute inflammatory disorders and evaluate current therapeutic strategies. Furthermore, we emphatically summarise the bioactive natural products, including terpenoids, flavonoids, alkaloids, and a xanthone, that prevent and treat acute inflammatory disorders by disrupting RAGE–ligand interactions and suppressing downstream oxidative stress and cytokine release. Integrating these molecular mechanisms with the pharmacological profiling of natural RAGE modulators provides a robust foundation for the development of next-generation therapeutic strategies to improve clinical outcomes in acute inflammatory disorders.